Premature graying as a consequence of compromised antioxidant activity in hair bulb melanocytes and their precursors
Behavioural and neurochemical consequences of chronic gut microbiota depletion during adulthood in the rat
For optimal preservation of the lyophilized LIPO-C powder, we recommend storing the vial in a refrigerator between 2C and 8C (36F and 46F)
When Lower BMI Patients Might Benefit From GLP-1 Therapy People with lower BMIs may pursue GLP-1 medications for legitimate reasons beyond traditional weight loss: managing binge eating disorder, reducing visceral fat while preserving muscle with proper nutrition, improving metabolic health markers like insulin resistance or blood sugar variability, or addressing food noise and compulsive eating patterns
Table 11: Results at Week 26 in a Trial Comparing TRESIBA to Insulin Glargine U-100 in Adult Patients with Type 2 Diabetes Mellitus on OAD(s)* Study G: TRESIBA Administered at the Same Time Each Day or Any Time Each Day as an Add-on to One and up to Three of the Following Oral Agents: Metformin, Sulfonylurea or Glinides or Pioglitazone in Adult Patients The efficacy of TRESIBA was evaluated in a 26-week randomized, open-label, multicenter trial in 687 patients with type 2 diabetes mellitus inadequately controlled on basal insulin alone, oral antidiabetic agents (OADs) alone or both basal insulin and OAD
as such, the power of the statistical analyses may not have been robust and the generalizability of the results should be interpreted with caution
